Cardiometabolic risk

Lipid/Metabolic

Examining the effects of CB1 blockade on CAD with IVUS: STRADIVARIUS results

5 COMMENTS - Jun 27, 2008 10:49 EDT

Ongoing interest exists in developing new pharmacologic approaches to address obesity and its sequelae of metabolic risk. Can intravascular ultrasound help us determine if we are on the right track to decreasing atherosclerotic progression with drug therapies? Join us for an insightful interview with Dr. Nissen on the STRADIVARIUS results, the benefits of IVUS and ongoing research examining CB1 blockade and its potential ability to decrease atherosclerotic progression by impacting more than just LDL reduction.

Lipid/Metabolic

Cardiometabolic risk in the spotlight: Which therapies should take center stage?

1 COMMENT - Dec 18, 2007 13:39 EST

Drs Smith, Rader, Nesto, Plutzky, Nemeroff, and Pagotto explore the interrelated role of cardiometabolic risk factors and analyze the mechanism of action and evidence for the effectiveness of cannabinoid receptor type 1 (CB1) blockade in CVD.

Lipid/Metabolic

Taming abdominal obesity: Preventing the attack of CVD and diabetes

Nov 21, 2007 10:45 EST

Recent studies reveal that weight loss can directly decrease CV mortality and increase longevity. How do clinicians determine the right combination of therapies to promote weight loss and decrease risk factors associated with CVD and diabetes? Join our international faculty for this stimulating discussion.

Lipid/Metabolic

Abdominal obesity: The perfect storm of CVD and diabetes

4 COMMENTS - Nov 16, 2007 15:00 EST

Should clinicians intervene for "overweight" patients or just for the "obese" regarding risk of CVD and diabetes? Does abdominal obesity create the perfect storm for catastrophic events? Join Professors Deanfield and Steg as they examine these questions through case study review.

Lipid/Metabolic

EASD 2007: Keys to prevention in diabetes and CV risk

Oct 17, 2007 15:30 EDT

The incidence of type 2 diabetes worldwide has increased from 30 million to 246 million over the last two decades, and continues to escalate. Some studies have revealed that approximately 80% of people with diabetes die of cardiovascular complications. This program will capitalize on cardiovascular risk, glycemic control and genetics influencing prevention and treatment in diabetes.

Lipid/Metabolic

Charting the course of CV risk in diabetes: Case study analysis

Jun 28, 2007 16:35 EDT

People with prediabetes have a 1.5-fold increased risk of cardiovascular disease compared to those with normal glucose levels. Once diabetes develops, CV complications frequently occur at an earlier age, resulting in premature death. Are we overlooking "warning signals" that CV injury is imminent? Join Drs Nesto and Hollander for this intriguing case study review.

Lipid/Metabolic

Running the race against CV risk in diabetes: Are we doing enough?

3 COMMENTS - Jun 27, 2007 09:00 EDT

Are you aware that people with diabetes who have no other cardiovascular risk factors may be as much as 5 times more likely to die from heart disease than non-diabetics? We target blood pressure, glucose and LDL levels... but is that enough? Should we focus more on weight loss? Join Drs Nesto, Hollander and Leiter as they explore other avenues for targeting CV risk.

Lipid/Metabolic

Juggling multiple risk factors to target global cardiometabolic risk

3 COMMENTS - Apr 3, 2007 13:39 EDT

With over 300 million obese individuals worldwide, the incidence of CVD and type 2 diabetes continue to escalate. The clinician is perplexed with managing multiple risk factors and juggling many treatment regimens. The potential for CB1 blockade represents a novel approach to addressing multiple synergistic risks by targeting the primary culprit — abdominal obesity.

Lipid/Metabolic

CB1 blockade and type 2 diabetes: The SERENADE study

Jan 25, 2007 13:56 EST

Diabetes affects approximately 194 million individuals worldwide. A large majority of these cases is due to type 2 diabetes and is linked to patients being overweight or obese. Reducing weight and controlling glucose in diabetic patients is important in order to minimize the risk of heart disease and other disabling complications. The SERENADE study examined the benefit of using CB1 blockade in type 2 diabetes to tackle cardiometabolic risk.

Lipid/Metabolic

Treating patients with CB1 blockade: The United Kingdom experience

4 COMMENTS - Dec 19, 2006 11:51 EST

With 23% of the population worldwide now obese, the risks of developing CV disease and type 2 diabetes are escalating. Lifestyle changes and current pharmacological interventions are having limited success. Explore case studies of CB1 blockade as part of the treatment regimen in countries where approved.

Lipid/Metabolic

CB1 blockade: Who's the ideal patient?

Nov 23, 2006 11:50 EST

In recent years, healthcare providers have become more aware of the risks of CVD and diabetes associated with abdominal obesity. What if the patient is not obese but simply overweight? How do we best assess the risk? What do we do when lifestyle changes and conventional pharmacological treatments are not successful? Evidence supports that cannabinoid-1 receptor (CB1) blockade therapy could be a promising alternative. If CB1 blockade becomes available in the United States, who will be the ideal candidate? Join our faculty as they explore these thought-provoking questions.

Lipid/Metabolic

Tackling abdominal obesity and cardiovascular risk around the world

Oct 12, 2006 10:32 EDT

Obesity is a growing epidemic around the world, with over 300 million obese individuals worldwide. The presence of abdominal obesity, which is easily determined by measuring waist circumference, has been identified as a contributing factor to cardiovascular risk. Ethnic and gender differences related to this disorder exist around the globe. This program will highlight the magnitude of the problem, explore gender and ethnic differences, and discuss strategies for managing the care of obese patients. Get the Canadian perspective on abdominal obesity and cardiovascular risk from Drs Abramson, Genest, and Lonn.

Lipid/Metabolic

Highlights from EASD 2006: Targeting CV risk in dysglycemic patients

Oct 6, 2006 15:26 EDT

The incidence of diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. One contributing factor to the escalating incidence is the global epidemic of abdominal obesity. Modern lifestyles and dietary habits are contributing to an increase in diabetes with a consequent rise in inter-related cardiometabolic risk factors. This program will review recent research findings related to the relationship between cardiometabolic risk factors and diabetes, with an emphasis on future trends for management of the patient with dysglycemia

Cardiometabolic risk

CB blockade with rimonabant

2 COMMENTS - Sep 5, 2006 11:45 EDT

Abdominal obesity is known to increase the risk of comorbidities such as insulin resistance, type 2 diabetes, dyslipidemia and hypertension, and has been linked to cardiovascular risk independently of body mass index. This health threat is largely due to an excess of intra-abdominal adipose tissue. CB1 receptor blockade has been shown to improve cardiometabolic risk factors both directly and indirectly by reducing intra-abdominal adiposity. This symposium will review the risks associated with abdominal obesity as well as data surrounding rimonabant, the first CB1 receptor antagonist.

Cardiometabolic risk

ADA 2006 Spotlight — The enigma of prediabetes: Impact on cardiovascular risk

1 COMMENT - Jun 20, 2006 16:20 EDT

According to the American Diabetes Association, 41 million people in the US aged 40-74 years have prediabetes and many will develop diabetes within 10 years. While glucose elevations may be below the threshold of diabetes, the patient is at risk for heart disease, retinopathy and kidney dysfunction. This program will highlight the ongoing debate defining prediabetes, the significance of early recognition of dysglycemia, and current research toward the reduction of CV risk in dysglycemic patients.

Cardiometabolic risk

Cardiometabolic risk in women: An equal opportunity killer

1 COMMENT - Jun 1, 2006 16:30 EDT

CVD remains the number one killer of both men and women. Sex disparities are well documented with some speculation that suboptimal preventive care and lack of awareness of personal CVD risk may contribute to poor outcomes in women. This program highlights the findings of a recently published large study which focused on screening of cardiometabolic risk in women.

Cardiometabolic risk

Knowledge of cardiometabolic risk: How do you measure up?

4 COMMENTS - May 12, 2006 12:00 EDT

Increasing awareness of the relationship between specific cardiometabolic risk factors and CVD remains at the forefront of medical education. Are you familiar with each risk factor and how it impacts your patients' health? Are you informed regarding the most recent research, treatment strategies, and potential new treatments on the horizon? It is highly important to measure your knowledge in this arena so you can optimize preventive measures in your patients. Take this opportunity to evaluate your knowledge and see how you measure up in comparison to your peers.

Cardiometabolic risk

Expert commentary: Evaluating the shape of our world: The IDEA survey

Mar 31, 2006 15:05 EST

Cardiovascular disease (CVD) remains the major cause of mortality worldwide and is responsible for approximately 17 million deaths per year. This figure is expected to rise to 24 million by 2030. Recent findings support that abdominal obesity is a much better predictor of CVD than weight or body mass index, but this information is not available in all countries. The IDEA survey addresses the assessment of abdominal obesity in 63 countries in over 177 000 patients presenting to primary care.

Cardiometabolic risk

ACC 2006 Focus on: Exploration of cardiometabolic risk

Mar 22, 2006 16:13 EST

Cardiometabolic risk combines classical risk factors (smoking, elevated cholesterol, hypertension, and diabetes) with emerging markers such as intra-abdominal obesity and insulin resistance. At the American College of Cardiology 2006 Scientific Sessions many presentations focused on assessing cardiovascular risk. This program will highlight several of those presentations and provide new insights related to ethnic/gender differences, new serum markers, economic impact, and strategies for assessing and treating patients at risk for cardiovascular disease.

Cardiometabolic risk

Looking beyond lipemic and glycemic control: Exploring CV risk reduction with statins, glitazones, and fenofibrates

1 COMMENT - Dec 6, 2005 14:02 EST

Recent debates and recommendations support the lower is better hypothesis regarding LDL-C levels. Diabetic patients with an increased risk of coronary events will most likely benefit from such aggressive lowering. Glitazones and fenofibrates have demonstrated great benefit in such patients. Dr Chris Cannon will discuss recent research findings related to these topics.

	Yes
	No
	I’m waiting for additional clinical trial results